Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium
{"title":"2 型糖尿病的精准医疗：瞄准 SGLT2 抑制剂治疗以保护肾脏","authors":"Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium","doi":"10.1101/2024.09.01.24312905","DOIUrl":null,"url":null,"abstract":"<strong>Background</strong> Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.","PeriodicalId":501419,"journal":{"name":"medRxiv - Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection\",\"authors\":\"Thijs T Jansz, Katherine G Young, Rhian Hopkins, Andrew P McGovern, Beverley M Shields, Andrew T Hattersley, Angus G Jones, Ewan R Pearson, Richard A Oram, John M Dennis, MASTERMIND Consortium\",\"doi\":\"10.1101/2024.09.01.24312905\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Background</strong> Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.\",\"PeriodicalId\":501419,\"journal\":{\"name\":\"medRxiv - Endocrinology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Endocrinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.01.24312905\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.01.24312905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection
Background Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
